Patents by Inventor Stefan Teigelkamp

Stefan Teigelkamp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof
    Patent number: 9469687
    Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: October 18, 2016
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Frank Vitzthum, Stefan Teigelkamp, Harald Althaus
  • Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof
    Patent number: 9453071
    Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PlGF), especially antibodies directed against the placental growth factor, and production and use thereof.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: September 27, 2016
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Frank Vitzthum, Stefan Teigelkamp, Harald Althaus
  • BINDING PARTNERS OF THE PLACENTAL GROWTH FACTOR, ESPECIALLY ANTIBODIES DIRECTED AGAINST THE PLACENTAL GROWTH FACTOR, AND PRODUCTION AND USE THEREOF
    Publication number: 20150299308
    Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.
    Type: Application
    Filed: June 1, 2015
    Publication date: October 22, 2015
    Inventors: Frank Vitzthum, Stefan Teigelkamp, Harald Althaus
  • Blood coagulation assays
    Patent number: 8304205
    Abstract: The invention relates to methods for determining the activity of a proteolytic coagulation factor of the blood coagulation cascade in a body fluid such as whole blood or plasma. A combination is provided in a reaction mixture. The combination comprises the sample and an activation agent for activating a proteolytic coagulation factor of the blood coagulation cascade or for activating the blood coagulation cascade. The effect of the activating on a reagent system comprising a cleavable moiety is evaluated. The cleavable moiety is or becomes bound to a chemiluminescent agent or a sensitizer agent or both. The chemiluminescent agent and the sensitizer agent are related in that, when in close proximity, energization of the sensitizer agent results in energization of the chemiluminescent agent. The effect of the activating is related to the activity of a proteolytic coagulation factor of the blood coagulation cascade wherein the effect is the extent of cleavage of the cleavable moiety.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: November 6, 2012
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Andreas Kappel, Andrea Lichte, Norbert Zander, Stefan Teigelkamp, Sabine Teigelkamp, legal representative, Carsten Schelp
  • Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof
    Patent number: 8063180
    Abstract: The invention relates to antibodies directed against F1+2, to the preparation and use thereof, especially in therapy and diagnosis. The antibodies bind to an epitope on the N-terminal half of the F2 fragment of prothrombin.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: November 22, 2011
    Assignee: Seimens Healthcare Diagnostics Products GmbH
    Inventors: Stefan Teigelkamp, Konrad Braun
  • Antibodies directed against prothrombin fragment F, the preparation and use thereof
    Patent number: 7795403
    Abstract: The invention relates to antibodies directed against F1+2, to the preparation and use thereof, especially in therapy and diagnosis. The antibodies bind to an epitope on the N-terminal half of the F2 fragment of prothrombin.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: September 14, 2010
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Stefan Teigelkamp, Konrad Braun
  • Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof
    Publication number: 20100158932
    Abstract: The invention relates to antibodies directed against F1+2, to the preparation and use thereof, especially in therapy and diagnosis. The antibodies bind to an epitope on the N-terminal half of the F2 fragment of prothrombin.
    Type: Application
    Filed: November 16, 2009
    Publication date: June 24, 2010
    Inventors: Stefan Teigelkamp, Konrad Braun
  • Blood Coagulation Assays
    Publication number: 20100086953
    Abstract: The invention relates to methods for determining the activity of a proteolytic coagulation factor of the blood coagulation cascade in a body fluid such as whole blood or plasma. A combination is provided in a reaction mixture. The combination comprises the sample and an activation agent for activating a proteolytic coagulation factor of the blood coagulation cascade or for activating the blood coagulation cascade. The effect of the activating on a reagent system comprising a cleavable moiety is evaluated. The cleavable moiety is or becomes bound to a chemiluminescent agent or a sensitizer agent or both. The chemiluminescent agent and the sensitizer agent are related in that, when in close proximity, energization of the sensitizer agent results in energization of the chemiluminescent agent. The effect of the activating is related to the activity of a proteolytic coagulation factor of the blood coagulation cascade wherein the effect is the extent of cleavage of the cleavable moiety.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 8, 2010
    Applicant: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Andreas Kappel, Andrea Lichte, Norbert Zander, Stefan Teigelkamp, Sabine Teigelkamp
  • Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof
    Publication number: 20090068679
    Abstract: The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.
    Type: Application
    Filed: May 8, 2006
    Publication date: March 12, 2009
    Inventors: Frank Vitzthum, Stefan Teigelkamp, Harald Althaus
  • Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof
    Publication number: 20050113562
    Abstract: The invention relates to antibodies directed against F1+2, to the preparation and use thereof, especially in therapy and diagnosis. The antibodies bind to an epitope on the N-terminal half of the F2 fragment of prothrombin.
    Type: Application
    Filed: November 19, 2004
    Publication date: May 26, 2005
    Inventors: Stefan Teigelkamp, Konrad Braun